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Abstract Mammary gland morphology and physiology
are supported by an underlying cellular differentiation
hierarchy. Molecular features associated with particular
cell types along this hierarchy may contribute to the bio-
logical and clinical heterogeneity observed in human breast
carcinomas. Investigating the normal cellular develop-
mental phenotypes in breast tumors may provide new
prognostic paradigms, identify new targetable pathways,
and explain breast cancer subtype etiology. We used
transcriptomic profiles coming from fluorescence-activated
cell sorted (FACS) normal mammary epithelial cell types
from several independent human and murine studies. Using
a meta-analysis approach, we derived consensus gene
signatures for both species and used these to relate tumors
to normal mammary epithelial cell phenotypes. We then
compiled a dataset of breast cancer patients treated with
neoadjuvant anthracycline and taxane chemotherapy regi-
mens to determine if normal cellular traits predict the
likelihood of a pathological complete response (pCR) in a
multivariate logistic regression analysis with clinical
markers and genomic features such as cell proliferation.
Most human and murine tumor subtypes shared some, but
not all, features with a specific FACS-purified normal cell
type; thus for most tumors a potential distinct cell type of
‘origin’ could be assigned. We found that both human
luminal progenitor and mouse fetal mammary stem cell
features predicted pCR sensitivity across all breast cancer
patients even after controlling for intrinsic subtype, pro-
liferation, and clinical variables. This work identifies new
clinically relevant gene signatures and highlights the value
of a developmental biology perspective for uncovering
relationships between tumor subtypes and their potential
normal cellular counterparts.
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Introduction
The mammalian breast is a dynamic organ, with major mor-
phological changes occurring during organogenesis, puberty,
pregnancy, lactation, and involution [1]. Underlying these
mammary gland changes is a complex cell hierarchy that
supports these processes [2–4]. The simplest model places the
multipotent mammary stem cell (MaSC) at the base of this
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hierarchy, having extensive, self-regenerative potential [5].
During mammary development, the MaSC has been proposed
to divide asymmetrically to produce basal/myoepithelial cells
as well as luminal progenitors (LumProg), which have more
restricted proliferative and differentiation capabilities [5].
LumProg cells are capable of further differentiation into
mature luminal (MatureLum) cells, such as estrogen receptor
(ER)-positive ductal epithelium, which have an even more
limited proliferative potential and some of which are termi-
nally differentiated [5].
Breast tumors may originate from several, if not all, of
the cell types within this complex mammary hierarchy.
These various cellular foundations for tumor initiation may
help explain the heterogeneous nature of human breast
tumors [6], which consist of multiple histological and
genomic subtypes; these genomic groups, which are
defined by their gene expression profiles, have become
known as the intrinsic subtypes of breast cancer and are
referred to as basal-like, claudin-low, HER2-enriched,
luminal A, and luminal B [7–10]. A simple etiological
explanation for these different subtypes involves a one-to-
one relationship between each intrinsic subtype and a dis-
tinct cell type of origin that largely maintains its pheno-
typic identity after oncogenic transformation; however,
both normal and neoplastic non-stem cells can acquire
stem-like properties, suggesting that the normal cell hier-
archy model could also include an element of reversibility
[11]. This also raises the possibility that molecular features
defining tumor subtypes, may be acquired during tumori-
genesis [12].
Genetically engineered mouse models (GEMMs) of
breast carcinoma develop heterogeneous tumors [13, 14],
but the extent to which they represent human disease is
an area of active investigation. We previously showed
that murine mammary tumors comprise at least 17 dis-
tinct intrinsic subtypes/classes, with eight classes being
identified as strong human subtype counterparts by gene
expression similarity [14]. As with human breast cancer,
the degree to which murine models reflect normal
mammary epithelial subpopulations requires further ana-
lysis. Characterization of the cellular features of these
murine classes is also needed to better determine their
preclinical utility, to shed light on trans-species associa-
tions [14], and to help interpret preclinical study obser-
vations [15–18].
Several studies have independently profiled fluores-
cence-activated cell sorted (FACS) purified normal mam-
mary cell types from both human [19–21] and murine [22,
23] mammary tissues. Here, we use a meta-analysis
approach to compare the transcriptomic profiles from
FACS-enriched mammary cell populations with each other
and with primary tumors. These data not only identify a
number of clinically relevant biomarkers that may be
useful for predicting chemotherapy benefit, but also sug-
gest a cell type of origin for many tumor subtypes.
Methods
Detailed methods can be found in Supplemental File 1.
Mammary cell subpopulation gene signatures
Gene expression measurements from FACS-enriched
mammary subpopulations were obtained from three human
and two murine published studies: GSE16997 [19],
GSE19446 [22], GSE27027 [23], GSE35399 [20], and
GSE50470 [21]. Using a meta-analysis approach, a con-
sensus ‘enriched’ gene signature was produced for each
mammary subpopulation. ‘Enriched’ signatures comprised
genes that were identified as being uniquely and highly
expressed (false discovery rate (FDR) \ 5 %) within a
given subpopulation as determined using a two-class
(subpopulation X versus all others) significance analysis of
microarrays (SAM) analysis [9, 24]. Each ‘enriched’ sig-
nature was further refined by supervised clustering using
the human UNC308 breast tumor dataset [9] to identify
subpopulation ‘features’, which were defined as having at
least ten genes with a Pearson correlation greater than 0.5
across all tumors [15, 25]. Expression scores for gene
signatures were determined by calculating the mean
expression of the signature within each tumor; all gene
signature lists are provided in Supplemental Table 1.
Mammary cell subpopulation centroids
Mammary cell subpopulation centroids were created using
the union of the ‘enriched’ epithelial gene signatures.
Distance weighted discrimination (DWD) single sample
predictor [26] was used to calculate the shortest Euclidean
distance between each tumor and each epithelial cell-
enriched centroid. Samples with a positive silhouette width
were considered to have a strong association with a given
subpopulation [27].
Chemotherapy response
A combined breast cancer gene expression dataset of
patients treated with neoadjuvant anthracycline and taxane
chemotherapy regimens was created from three public
datasets: GSE25066 [28], GSE32646 [29], and GSE41998
[30]. Univariate (UVA) and multivariate (MVA) logistic
regression analyses were used to determine if gene signa-
tures derived from normal cell populations were capable of
predicting pathological complete response (pCR).
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Results
Comparison of human mammary subpopulation
transcriptomic datasets
Several groups have independently obtained transcriptomic
profiles of normal human breast cells and compared the
genomic biology of these different cell types with human
tumors [19–21]. In these studies, normal mammary tissues
obtained from female donors were FAC sorted using cell
surface markers to enrich for specific mammary subpopu-
lations before microarray analysis (Table 1; Fig. 1). While
these initial studies were important, the datasets themselves
were relatively small (n = 12 for Lim et al. [19], n = 72
for Shehata et al. [20], n = 18 for Prat et al. [21]), and few
if any comparisons across studies were performed.
Importantly, FACS-based cell fractionation can only enrich
for specific subpopulations. Therefore, transcriptomic
profiles reflect features of other contaminating cell types to
varying degrees. As such, study-specific biases may be
present in any single dataset; therefore, we used consensus
information from all three FACS-enriched human tran-
scriptomic datasets to reduce technical and study-specific
biases.
Following DWD normalization [26], an unsupervised
cluster of the most variably expressed genes was performed
using Gene Cluster v3.0 by selecting all genes with an
absolute log2 expression value greater than three in at least
four samples (212 genes) (Fig. 2a). In general, the four
major array dendrogram nodes correspond to the four
FACS-enriched mammary subpopulations, indicating that
the most highly and variably expressed genes are similarly
expressed across the different studies. Even when using all
genes in the dataset, there is a high Pearson correlation
within a given subpopulation across studies and low cor-
relations to other subpopulations (Fig. 2b).
On a per-sample basis, the first principle component
separated the stroma and adult mammary stem cell (aMaSC)
samples from the LumProg and MatureLum samples
(Fig. 2c). The second principle component separated the
stroma and aMaSC samples into distinct groups, while the
third principle component separated the LumProg and Ma-
tureLum samples into distinct groups. The aMaSC subpop-
ulation displayed the highest level of variation, which is
likely attributable to varying degrees of contamination by
other cell types.
Human mammary cell subpopulation enriched gene
signatures
As shown in Fig. 2, there is a natural degree of variation
between samples of a given subpopulation. We therefore
developed gene signatures for each human mammary
subpopulation by integrating consensus information across
all three datasets (Table 1) to identify the highest confi-
dence subpopulation-specific genes. First, genes highly
expressed (FDR \ 5 %) within each mammary subpopu-
lation were found using a two-class (subpopula-
tion X versus all others) SAM analysis [24] within each
dataset [19–21]. Second, the overlap of genes highly
expressed within a particular subpopulation across studies
was determined. Lastly, as it is possible in the above
analysis to have the same gene in the signature of more
than one subpopulation, genes that were identified to be
significantly associated with more than one subpopulation
were also removed. This resulted in a single, consensus
Homo sapiens-enriched (HsEnriched) signature per sub-
population (Fig. 3a). The average Euclidean distance was
Table 1 Human FACS-enriched normal mammary cell subpopulation studies
Enriched population FACS markers Species Source Abbreviation Reference
Stroma CD49fneg, EpCAMneg Human Adult aStr-Lim09 Lim et al. [19]
CD49fneg, EpCAMneg Human Adult aStr-Shehata Shehata et al. [20]
CD49fneg, EpCAMneg Human Adult aStr-Prat Prat et al. [21]
Stem cell CD49fpos, EpCAMneg Human Adult aMaSC-Lim09 Lim et al. [19]
CD49fpos, EpCAMneg Human Adult aMaSC-Shehata Shehata et al. [20]
CD49fpos, EpCAMneg Human Adult aMaSC-Prat Prat et al. [21]
Luminal progenitor CD49fpos, EpCAMpos Human Adult LumProg-Lim09 Lim et al. [19]
CD49fpos, EpCAMpos Human Adult LumProg-Shehata Shehata et al. [20]
CD49fpos, EpCAMpos Human Adult LumProg-Prat Prat et al. [21]
Mature luminal CD49fneg, EpCAMpos Human Adult MatureLum-Lim09 Lim et al. [19]
CD49fneg, EpCAMpos Human Adult MatureLum-Shehata Shehata et al. [20]
CD49fneg, EpCAMpos Human Adult MatureLum-Prat Prat et al. [21]
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Fig. 1 Flowchart of analysis.
Normal mammary tissue
biopsies were taken from female
patients (a) and FACS-enriched





expression microarrays by three
different studies (c). Within
each study, genes highly
expressed within each
subpopulation were determined




studies were determined to
identify ‘enriched’ gene
signatures (e). Each ‘enriched’
signature was refined by
supervised hierarchical
clustering to identify gene
‘features’ highly correlated
across a diverse set of human
breast tumors (f). These gene
signatures were then used for
clinical testing (g)
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determined using a 10-fold cross validation for each nor-
mal mammary subpopulation sample to centroids created
using either the HsEnriched-derived gene signatures or to
centroids created using the gene signatures derived sepa-
rately from each human study (Supplemental Fig. 1). The
HsEnriched centroids had a significantly reduced Euclid-
ean distance (*70 %) to each mammary subpopulation
(t test p \ 0.0001), indicating greater specificity for the
consensus HsEnriched signatures when compared with any
individual dataset’s subpopulation signature.
We next evaluated the utility of these signatures for
distinguishing human tumor subtypes. Figure 3b displays
the standardized average expression of each HsEnriched
signature across the human intrinsic breast tumor subtypes
[7, 9] using over 3,000 tumors [9, 31, 32]. The aStr-
HsEnriched signature was highest in claudin-low and
normal-like tumors. Interestingly, claudin-low tumors also
highly express the aMaSC-HsEnriched signature. High
expression of the aMaSC-HsEnriched signature in claudin-
low tumors is unlikely an artifact of stromal cells in these
tumors since the Pearson correlation between the aStr-
HsEnriched and aMaSC-HsEnriched signatures was -0.19
across the normal human mammary samples. The LumProg
and MatureLum-HsEnriched signatures were most highly
expressed in basal-like and luminal subtype tumors,
respectively (Fig. 3b).
We noted a considerable degree of signature variation
within a subtype, indicating that it is not necessarily the
case that all tumors of a given subtype share features with
the same normal cell type. A nearest centroid predictor
with a 10-fold cross validation error rate of 4.8 % was
created to individually determine which normal mammary
epithelial subpopulation is most similar to each tumor.
Samples with positive silhouette widths [27] were consid-
ered to have a strong association with their particular
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Fig. 2 Comparison of mammary subpopulations across studies.
a Unsupervised hierarchical clustering was performed with the
normal human mammary subpopulation dataset using any gene that
had a log2 absolute expression value greater than three in at least four
samples. b Pearson correlations were determined between the average
expressions of each study’s subpopulations using all genes. c The first
three principle components were determined across the human
mammary subpopulation dataset
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‘unclassified’ [33] (Fig. 3c). Specifically, 94 % of basal-
like tumors had LumProg expression profiles. The claudin-
low subtype had the highest percentage of tumors classified
as aMaSC (18 %), although most claudin-low tumors were
classified as having LumProg features (59 %). The HER2-
enriched subtype was predominantly classified as having
LumProg expression features. The luminal A and B sub-
types were most similar to the MatureLum subpopulation.
Murine mammary cell subpopulation enriched gene
signatures
Several groups have also profiled normal murine mammary
cell subpopulation expression features using FACS [22, 23]
(Table 2). In addition to highlighting conserved expression
features across species [22], murine studies are uniquely
positioned to enable comparisons with developmental
states not easily accessed in humans, including early fetal
development [23]. We were particularly interested in fetal
mammary stem cells (fMaSC) [23], which is a distinct cell
population not captured in any human study performed
thus far (Table 3). Using the same approach that we used to
derive the HsEnriched signatures, we created Mus muscu-
lus-enriched (MmEnriched) signatures for each murine
mammary subpopulation (Fig. 4a) [22, 23].
We calculated the standardized average expression of
each MmEnriched signature across the murine intrinsic
subtypes/classes (Fig. 4b) [14]. As in human tumors, the
Str-MmEnriched signature was most highly expressed in
Normal-likeEx and Claudin-lowEx; this common feature was
anticipated given the high similarity of these two classes to
their human subtype counterparts and their known enrich-
ment for stroma-associated genes [14, 23]. The aMaSC-
MmEnriched signature was most highly expressed in
Class14Ex and to a slightly lesser extent in Wnt1-LateEx,
Wnt1-EarlyEx, p53null-BasalEx, and Squamous-likeEx. The
fMaSC-MmEnriched signature was most highly expressed
in WapINT3Ex, which is consistent with the finding that Int3
(Notch4) inhibits mammary cell differentiation [34, 35].
The LumProg-MmEnriched signature was highest in
PyMTEx and NeuEx. This finding was unexpected given












































































































































































































































































































































Fig. 3 Homo sapiens-enriched gene signatures. a HsEnriched gene
signatures were identified for each mammary subpopulation. First, the
overlap of genes highly expressed within each subpopulation across
studies was determined. This overlapping gene set was further filtered
to remove genes also identified as enriched in another subpopulation
to limit the signature to genes specific to an individual subpopulation.
The remaining genes comprised the HsEnriched gene signature for
that subpopulation, as indicated by the shaded box. b The
standardized average expression of the four HsEnriched gene
signatures was calculated across three human datasets and displayed
by intrinsic tumor subtype. c A nearest centroid predictor using the
HsEnriched gene signatures was used to determine which epithelial
features each tumor most represented. To reduce spurious findings,
any tumor with a negative silhouette width was considered to have a
weak association and was labeled as ‘unclassified’
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luminal human tumors [13, 14]. Lastly, the MatureLum-
MmEnriched signature was most highly expressed in
Stat1Ex and Class14Ex. Both the Stat1-/- and Pik3ca-
H1047R mouse models, which define these two classes
respectively, are often ER positive [36, 37], and these data
suggest that they have MatureLum features. Class14Ex also
exhibited significant expression of the aMaSC-MmEn-
riched signature, indicating that these tumors contain a
mixture or share features of multiple cell types.
Consistent with Fig. 4b, 91 % of WapINT3Ex tumors were
classified as having fMaSC features in a nearest centroid pre-
dictor analysis. Mouse luminal classes of breast carcinoma
(Erbb2-likeEx, MycEx, PyMTEx, and NeuEx) were most similar
to LumProg cells, which again were unexpected but consistent
with previous findings [22, 38]. Wnt1-EarlyEx, p53null-
BasalEx, and Squamous-likeEx tumors had primarily aMaSC
features. Interestingly, Claudin-lowEx and to a lesser extent C3-
TagEx tumors also had aMaSC features. All Stat1Ex tumors had
MatureLum features, consistent with being ER positive [36].
LumProg and fMaSC features predict neoadjuvant
chemotherapy response
Breast tumors respond heterogeneously to neoadjuvant
chemotherapy treatment [15]. We hypothesized that cellular
features of normal mammary subpopulations may identify
tumors most likely to respond to neoadjuvant chemotherapy.
To test this, we compiled a dataset of 702 neoadjuvant
anthracycline and taxane chemotherapy-treated patients
(Supplemental Table 2).
Although genes within each ‘enriched signature’ are
highly correlated within their respective normal cell
subpopulation, it does not necessarily follow that all genes
within a given normal cell signature would be as coor-
dinately regulated in tumors. Therefore, we subdivided
each signature into smaller features (feature1, feature2,
etc.) that are coordinately expressed in tumors, reasoning
that such refined ‘features’ may be more clinically robust.
All ‘enriched’ and refined ‘features’ were tested for their
ability to predict pCR to neoadjuvant chemotherapy in a
UVA (Supplemental Table 3). UVA significant signatures
(p \ 0.05) were then considered in a MVA with age, ER
status, PR status, HER2 status, tumor stage, PAM50
subtype [39], and PAM50 proliferation score [39] to
determine if any mammary subpopulation ‘features’
added novel information for predicting pCR (Supple-
mental Table 4).
Six normal mammary gene signatures were UVA and
MVA significant (Supplemental Tables 3 and 4), with the
95 % UVA odds ratio of these six signatures and all other
‘enriched signatures’ displayed in Fig. 5a. Interestingly,
the LumProg-HsEnriched and LumProg-HsEnriched-fea-
ture1 signatures, both of which were highly correlated
(Fig. 5b), were significant in the UVA and MVA analyses,
indicating that tumors with LumProg features are more
likely to respond to neoadjuvant treatment. Importantly,
this response was independent of proliferation, as high-
lighted by their low correlation to the PAM50-Proliferation
gene signature (Fig. 5b).
Interestingly, the fMaSC-MmEnriched signature refined
into two distinctly opposite, highly significant signatures in
both the UVA and MVA (Supplemental Table 3, 4;
Fig. 5b, c). While the fMaSC-MmEnriched signature was
highest in basal-like tumors, the refined signatures varied,
Table 2 Murine FACS-enriched normal mammary cell subpopulation studies
Enriched population FACS markers Species Source Abbreviation Reference
Stroma Cd24neg/low/med Mouse Fetal fStr-Spike Spike et al. [23]
Cd29neg, Cd24neg Mouse Adult aStr-Lim10 Lim et al. [22]
Stem cell Cd49fhi, Cd24hi Mouse Fetal fMaSC-Spike Spike et al. [23]
Cd49fhi, Cd24med Mouse Adult aMaSC-Spike Spike et al. [23]
Cd29pos, Cd24pos, Cd61pos Mouse Adult aMaSC-Lim10 Lim et al. [22]
Luminal progenitor Cd29neg, Cd24pos, Cd61pos Mouse Adult LumProg-Lim10 Lim et al. [22]
Mature luminal Cd29neg, Cd24pos, Cd61neg Mouse Adult MatureLum-Lim10 Lim et al. [22]
Table 3 Gene set analysis of human and murine cell subpopulations
Murine subpopulation Human subpopulation
Str aMaSC LumProg MatureLum
Str 0.044 – – –
fMaSC – – 0.4395 0.4395
aMaSC – 0.044 – –
LumProg – – 0.042 0.386
MatureLum – 0.464 0.306 0.004
A comparative analysis of each human subpopulation versus each
murine subpopulation was performed using GSA. The FDR is dis-
played for all comparisons with a positive association. Statistically
significant associations (FDR \ 0.05) are bolded
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with fMaSC-MmEnriched-feature1 (Fig. 5d) being highest
in basal-like tumors and fMaSC-MmEnriched-feature2
(Fig. 5e) expressed in luminal tumors. Tumors with
fMaSC-MmEnriched-feature1 expression were more likely
to respond to neoadjuvant chemotherapy, while those
tumors with fMaSC-MmEnriched-feature2 were more
resistant. The fMaSC-MmEnriched-feature1 signature was
very highly correlated with the LumProg-HsEnriched sig-
natures (Fig. 5b), sharing four genes in common (Fig. 5d).
These results support the hypothesis that subsets of genes
within the larger ‘enriched signature’ are likely regulated
by different biological mechanisms.
bFig. 4 Mus musculus-enriched gene signatures. a MmEnriched gene
signatures were identified for each mammary subpopulation. First, the
overlap of genes highly expressed within each subpopulation across
studies was determined. This overlapping gene set was further filtered
to remove genes also identified as enriched in another subpopulation
to limit the signature to genes specific to an individual subpopulation.
The remaining genes comprised the MmEnriched gene signature for
that subpopulation, as indicated by the shaded box. b The standard-
ized average expression of the five MmEnriched gene signatures was
calculated across a murine dataset and displayed by intrinsic tumor
class. c A nearest centroid predictor using the MmEnriched gene
signatures was used to determine which epithelial features each tumor
most represented. To reduce spurious findings, any tumor with a
negative silhouette width was considered to have a weak association
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Fig. 5 fMaSC-enriched gene signatures. a The univariate logistic
regression odds ratio predicting pathologic complete response to
neoadjuvant anthracycline and taxane chemotherapy was determined
using a 702 patient dataset, with the 95 % confidence interval shown
as a forest plot. A single ‘*’ indicates that the signature was univariate
significant, while ‘***’ indicates that the signature was both
univariate and multivariate significant (p \ 0.05). b Pearson
correlations of multivariate significant gene signatures and prolifer-
ation were determined. c The standardized average expression of the
fMaSC-MmEnriched signature and its two refined signatures were
calculated across three human datasets and displayed by intrinsic
tumor subtype. d Genes in the fMaSC-MmEnriched-refined1 signa-
ture. e Genes in the fMaSC-MmEnriched-refined2 signature
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Discussion
Normal mammary gland physiology is supported by an
underlying, complex cell hierarchy [2–5]. The simplest
model treats differentiation from mammary stem cells to
progenitor cells to mature cells as unidirectional, but recent
observations indicate that bidirectional processes are also
possible for normal and neoplastic cells [11]. This differ-
entiation plasticity may allow tumors to acquire cell fea-
tures foreign to the initial cell-of-origin or to lose native
features through the accumulation of specific genetic
aberrations [40].
Regardless of how different cellular traits are acquired,
it is critical to identify the ‘current’ normal cellular features
within a tumor, and therefore, we first analyzed the
expression profiles of normal human and mouse mammary
epithelial cell subpopulations [19–23]. We chose to use
nomenclature that maintains continuity with the literature.
However, these terms should be considered provisional as
the complete biological profiles of these FACS fractions
are investigated [4]. Recent work by Prater et al. [41] found
that mouse ‘LumProg’ cells (CD49f?, EpCAM?) have
complete mammary gland repopulating potential, indicat-
ing that ‘LumProg’ may be a misnomer. Importantly, even
if our understanding and naming of these cell subpopula-
tions change, only the retrospective interpretation of the
data presented here will be affected, not the data itself.
Using a meta-analysis approach, FACS-purified mam-
mary epithelial cell subpopulation ‘enriched’ gene signa-
tures were derived and a nearest centroid predictor was
developed to identify which normal mammary subpopula-
tion each human and mouse tumor most represented using
over three thousand human patients and 27 mouse models
of mammary carcinoma [14]. While these analyses imply a
cell-of-origin for a given tumor, additional experiments
(e.g., lineage tracing) will be required to unequivocally
determine this. Nevertheless, these associations at the very
least identify which normal mammary subpopulation a
given tumor most represents in its current state.
With this in mind, several associations between both the
human and mouse intrinsic subtypes and specific normal
cell subpopulations were observed. First, human basal-like
tumors have been referred to as ‘undifferentiated’, which is
consistent with their exhibiting LumProg [19] and fetal
MaSC features [23]. Three mouse classes have been
identified to be human basal-like counterparts: MycEx,
p53null-BasalEx, and C3-TagEx [14]. MycEx tumors were
the most similar to the LumProg cell profile. By contrast,
both p53null-BasalEx and C3-TagEx tumors had adult
MaSC features. These results indicate that MycEx tumors
share similar cell features as their human basal-like coun-
terpart, making it an attractive mouse model for studying
basal-like tumors with aberrant Myc signaling [10, 42].
Interestingly, neither p53null-BasalEx nor C3-TagEx tumors
had strong LumProgs features, indicating that their asso-
ciation with human basal-like tumors is more likely driven
by their underlying genetics [10].
Human claudin-low tumors had heterogeneous normal
cell features. While most were similar to LumProg cells,
the claudin-low subtype also had the largest percentage of
tumors classified as adult MaSC. Given that claudin-low
tumors are enriched with epithelial-to-mesenchymal tran-
sition features [9, 43, 44], our results suggest that these
tumors may originate from the LumProg population prior
to acquiring adult MaSC and/or mesenchymal features.
Similarly, mouse Claudin-lowEx tumors were also strongly
associated with the adult MaSC population, indicating that
such tumors may be the closest analogs of the subset of
human claudin-low tumors with adult MaSC features.
Human HER2-enriched tumors were the most similar to
the LumProg subpopulation. This is a novel finding and
may explain why both human basal-like and HER2-enri-
ched subtype tumors show high TP53 mutation frequencies
([70 %) and widespread chromosomal instability [10].
These data could suggest that the normal LumProg cell is
somehow extremely dependent on TP53 function. The
murine Erbb2-likeEx class has been identified as a mouse
counterpart for human HER2-enriched tumors [14] and was
shown here to also have LumProg features.
When analyzing the human luminal A and B subtypes, a
clear association with normal MatureLum cells was
observed. The murine NeuEx class is a proposed counter-
part for human luminal A tumors [14], yet these mouse
tumors were most similar to normal mouse LumProg cells.
The MycEx class was also identified to resemble human
luminal B tumors [14]. As discussed, MycEx tumors have
LumProg features; therefore, most mouse luminal A/B
tumor models do not share the same normal cell features as
their human tumor counterparts. These differences may
reflect limitations of model system design, as tumors within
these mouse classes are primarily driven by either the WAP
or MMTV promoter. These differences in cell features,
however, indicate that the trans-species associations
observed previously [14] are possibly driven by the
genetics of each mouse model. Nevertheless, broad
molecular features are conserved between these human–
murine counterparts [14]. Therefore, we propose that these
mouse models retain significant preclinical utility provided
that shared versus distinct molecular features are taken into
account.
Neoadjuvant chemotherapy is a common approach for
treating breast tumors, but only a relatively low percentage
of patients have a pCR (*20 % overall). We tested the
clinical significance of normal cellular features for pre-
dicting pCR using a combination of UVA and MVA
logistic regression analyses. Human LumProg and mouse
434 Breast Cancer Res Treat (2015) 149:425–437
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fetal MaSC expression features were identified as predic-
tive of pCR sensitivity across all breast cancer patients.
More specifically, LumProg-HsEnriched-feature1 and
fMaSC-MmEnriched-feature1 were highly expressed in
basal-like tumors. This is consistent with the clinical
observation that basal-like tumors have better neoadjuvant
chemotherapy response rates since higher expression of
these normal cell signatures was associated with a higher
likelihood of pCR. Distinct from these signatures, tumors
with high expression of fMaSC-MmEnriched-feature2
were more resistant to neoadjuvant chemotherapy. Not
surprisingly, this signature was most highly expressed in
luminal A and B tumors, consistent with the clinical
observation that these subtypes have lower chemotherapy
response rates. Importantly, these signatures remained
significant even after controlling for intrinsic subtype,
proliferation, and clinical variables in the MVA analysis;
thus these normal cell signatures add information even
when tumor subtype and clinical features are known. It is
presently unknown whether tumors with these features
arise from a LumProg or fetal MaSC cell-of-origin or
acquire these features during tumorigenesis. Whether these
features are acquired or inherent, the ‘current’ cellular
traits of a tumor are likely most important as these appear
to be a major determinant of chemotherapy sensitivity. The
biological explanation for why LumProg and fetal MaSC
expression features predict tumor responsiveness to neo-
adjuvant chemotherapy will need to be explored further,
but it is likely linked to the common genetic features of
TP53 loss [45], RB-pathway loss [46], and high prolifera-
tion status [47], as well as other inherent characteristics of
these cellular states. This work highlights the efficacy of
studying the normal mammary gland cell hierarchy and
development to provide insights into human tumor therapy
responsiveness.
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